Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...
Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC
Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...
Pharmabiz2d
Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC
Pfizer’s Braftovi+Mektovi shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic NSCLC: New York Monday, September 16, 2024, 10:00 Hrs [IST ...
Armed robbery in Revesby3d
Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Benefits in NSCLC
Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...
devdiscourse2d
Health Alert: Latest Updates from India, Uganda, and Pfizer
A summary of current health news, including a Nipah virus death in Kerala, an mpox case rise in Uganda, and Pfizer's efforts ...
Drug & Device Trials
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...
Reuters4d
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi ...
Nasdaq4d
Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC
(RTTNews) - Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI (encorafenib) in combination ...